From Dr Sharman's blog on ASCO 2015.
abstracts.asco.org/156/Abst...
Jeff
Meet this triplet: From Dr Sharman's blog on... - CLL Support
Meet this triplet
Written by
Justasheet1
To view profiles and participate in discussions please or .
1 Reply
•
AussieNeilPartnerAdministrator
Well spotted Jeff. Not too bad side effect wise and a very encouraging Overall Response Rate (ORR) - well other than for Richters Transformation patients unfortunately, particularly considering this is a heavily pre-treated and high risk group. I expect both side effects and ORR will increase with dosage increase.
Now if only these patients can achieve remission then not progress if/when they go off the treatment.
I wonder how long before this combination is offered as a first line treatment?
Neil
Not what you're looking for?
You may also like...
How well does this site meet your needs in terms of content?
Here's your opportunity to respond with feedback on what you like about the content on this site...
Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
Oncology live May 06, 2020
The time-limited triplet of umbralisib, ublituximab, and venetoclax...
Triplet Regimen Shows Promise in CLL -Zanubrutinib, obinutuzumab, & venetoclax combo achieves rapid undetectable MRD -MedPageToday -07/07/20
Treatment triple-header news from the MedPage Today. From the article:
At the American Society...
New to this!
I'm new in this forum. Was diagnosed with CLL 3.5 years ago, aged 48, on a routine blood test. What...
Anyone see this?
https://topicalthunder.com/2019/05/15/new-simple-injection-to-cure-cancer-getting-staggering-results
New to this
This is huge!
Treatment this week 
Is this normal?
New to this
